Version history

{
  "session_id": "sess_SDA-2026-04-13-gap-pubmed-20260410-174607-708e8d91",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"id\": \"H2\",\n      \"title\": \"Phagocytic 'Viral Sink' Clearance Mechanism\",\n      \"composite_score\": 0.63,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.60,\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.60,\n        \"feasibility\": 0.60,\n        \"therapeutic_potential\": 0.65,\n        \"druggability\": 0.55,\n        \"safety_profile\": 0.45,\n        \"competitive_landscape\": 0.70,\n        \"data_availability\": 0.55,\n        \"reproducibility\": 0.65\n      },\n      \"evidence_for\": [\n        {\"claim\": \"MERTK is the primary receptor for efferocytosis of apoptotic bodies\", \"pmid\": \"16148958\"},\n        {\"claim\": \"Mertk-/- mice showed enhanced viral replication and spread\", \"pmid\": \"26523970\"},\n        {\"claim\": \"Protein S binds phosphatidylserine-exposing cells and viral envelope phosphatidylserine\", \"pmid\": \"20194607\"},\n        {\"claim\": \"Viral apoptotic bodies can seed further infection if not cleared\", \"pmid\": \"22103293\"},\n        {\"claim\": \"Fc-DN30 agonist antibody provides proof-of-concept for MERTK agonism\", \"pmid\": \"29141986\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Temporal mismatch: efferocytosis takes hours to days but viral neuroinvasion occurs within hours\", \"pmid\": null},\n        {\"claim\": \"Most neurotropic viruses replicate in epithelial cells before CNS arrival, not primarily cell-associated\", \"pmid\": null},\n        {\"claim\": \"PMID:26523970 shows enhanced viral replication but does not demonstrate defective efferocytosis as the cause\", \"pmid\": \"26523970\"},\n        {\"claim\": \"Efferocytosis cannot clear intracellular replication compartments\", \"pmid\": null}\n      ],\n      \"key_citations\": [\"26523970\", \"16148958\", \"20194607\", \"29141986\"],\n      \"recommended_experiments\": [\n        \"Viral load time course (peripheral + CNS) at 6h, 12h, 24h, 48h, 72h\",\n        \"Bone marrow chimera to separate hematopoietic vs stromal contribution\",\n        \"rProtein S dosing pharmacodynamics in WT mice\",\n        \"Brain penetration assessment of Protein S/Gas6-Fc\"\n      ],\n      \"development_timeline\": \"4-6 years to IND if starting from antibody; 6-8 years from small molecule\",\n      \"risk_factors\": [\"Thrombosis (Protein S anticoagulant domain)\", \"Potential to enhance viral entry via phosphatidylserine binding\", \"Broad immunosuppression risk\"],\n      \"unifying_theme\": \"TAM receptor-mediated clearance of infected apoptotic debris prevents viral spread and DAMP release that would damage BBB\"\n    },\n    {\n      \"rank\": 2,\n      \"id\": \"H1\",\n      \"title\": \"BBB-Protective 'Immune Checkpoint' Timing Hypothesis\",\n      \"composite_score\": 0.45,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.45,\n        \"evidence_strength\": 0.40,\n        \"novelty\": 0.75,\n        \"feasibility\": 0.40,\n        \"therapeutic_potential\": 0.50,\n        \"druggability\": 0.30,\n        \"safety_profile\": 0.35,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.45,\n        \"reproducibility\": 0.50\n      },\n      \"evidence_for\": [\n        {\"claim\": \"MERTK deficiency led to increased viral loads and enhanced leukocyte infiltration into the CNS with elevated pro-inflammatory cytokines\", \"pmid\": \"26523970\"},\n        {\"claim\": \"TAM receptors suppress TLR signaling via SOCS1/SOCS3 induction\", \"pmid\": \"16343641\"},\n        {\"claim\": \"BBB tight junction disruption by TNF-α is well-documented\", \"pmid\": \"10760258\"},\n        {\"claim\": \"TAM agonization preserves BBB integrity in other contexts\", \"pmid\": \"29141986\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Mechanism not demonstrated: 'timing' as critical factor has no molecular mechanism\", \"pmid\": null},\n        {\"claim\": \"Confuses correlation with causation: elevated TNF-α/IL-1β could be consequence of higher viral loads\", \"pmid\": null},\n        {\"claim\": \"If TAM provides constitutive BBB protection, why isn't there baseline dysfunction in uninfected TAM-deficient mice?\", \"pmid\": null},\n        {\"claim\": \"Predictive ambiguity: 'early' vs 'during early infection' windows not operationally defined\", \"pmid\": null}\n      ],\n      \"key_citations\": [\"26523970\", \"16343641\", \"10760258\"],\n      \"recommended_experiments\": [\n        \"TNF-α blockade in Mertk-/- mice at matched viral titers to WT\",\n        \"Measure BBB tight junction expression at equivalent viral loads\",\n        \"Direct CNS inoculation comparison between WT and Mertk-/-\"\n      ],\n      \"development_timeline\": \"Requires mechanistic definition before investment; estimated 5-7 years\",\n      \"risk_factors\": [\"Precision timing required (no biomarker for 'correct window')\", \"Immunosuppression could worsen antiviral responses\", \"No tools for timed agonism exist\"],\n      \"unifying_theme\": \"TAM receptors function as temporal immune brakes to prevent premature BBB disruption by suppressing early pro-inflammatory responses\"\n    },\n    {\n      \"rank\": 3,\n      \"id\": \"H4\",\n      \"title\": \"Type I IFN 'Shielding' vs 'Damage' Paradox Resolution\",\n      \"composite_score\": 0.46,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.50,\n        \"evidence_strength\": 0.35,\n        \"novelty\": 0.80,\n        \"feasibility\": 0.40,\n        \"therapeutic_potential\": 0.45,\n        \"druggability\": 0.30,\n        \"safety_profile\": 0.25,\n        \"competitive_landscape\": 0.50,\n        \"data_availability\": 0.35,\n        \"reproducibility\": 0.50\n      },\n      \"evidence_for\": [\n        {\"claim\": \"Type I IFN can be protective or pathogenic depending on timing and magnitude\", \"pmid\": \"27279225\"},\n        {\"claim\": \"STAT1 activation linked to BBB disruption in neuroinflammation\", \"pmid\": \"29491009\"},\n        {\"claim\": \"MMP9-mediated tight junction degradation in neuroinflammation documented\", \"pmid\": \"25666004\"},\n        {\"claim\": \"Elevated inflammatory cytokines in Mertk-deficient mice\", \"pmid\": \"26523970\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Type I IFN is generally protective in neurotropic viral infections - hypothesis inverts established understanding\", \"pmid\": \"16439465\"},\n        {\"claim\": \"PMID:26523970 mentions IFN-γ (Type II), not Type I IFN (α/β) - conflation undermines specificity\", \"pmid\": \"26523970\"},\n        {\"claim\": \"JAK inhibitors (blocking IFN signaling) worsen viral CNS infections - contradicts therapeutic prediction\", \"pmid\": \"28129924\"},\n        {\"claim\": \"Mechanistic complexity without supporting data: no evidence for TAM sensing IFN duration\", \"pmid\": null}\n      ],\n      \"key_citations\": [\"27279225\", \"29491009\", \"25666004\", \"26523970\"],\n      \"recommended_experiments\": [\n        \"Anti-IFNAR1 antibody treatment in WT vs Mertk-/- mice before infection\",\n        \"ISG expression kinetics (Mx1, Ifit1, Oas1) at 6h, 12h, 24h\",\n        \"MMP9/2 inhibitor rescue of Mertk-/- phenotype\"\n      ],\n      \"development_timeline\": \"Not recommended - conflicting pharmacologies required\",\n      \"risk_factors\": [\"Therapeutic prediction contradicts field understanding\", \"Type I IFN blockade would likely be harmful\", \"No biomarker for protective 'window'\"],\n      \"unifying_theme\": \"TAM receptors may gate a dual-phase IFN response to prevent JAK-STAT-driven BBB permeability, though this remains highly speculative\",\n      \"special_note\": \"Should be substantially revised or abandoned given contradictions with established IFN biology\"\n    },\n    {\n      \"rank\": 4,\n      \"id\": \"H5\",\n      \"title\": \"Viral Entry Receptor Downregulation Hypothesis\",\n      \"composite_score\": 0.38,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.30,\n        \"evidence_strength\": 0.35,\n        \"novelty\": 0.65,\n        \"feasibility\": 0.40,\n        \"therapeutic_potential\": 0.35,\n        \"druggability\": 0.25,\n        \"safety_profile\": 0.40,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.30,\n        \"reproducibility\": 0.50\n      },\n      \"evidence_for\": [\n        {\"claim\": \"LDLR family members serve as entry receptors for some viruses\", \"pmid\": \"25217958\"},\n        {\"claim\": \"TAM receptors regulate LDLR-related protein trafficking\", \"pmid\": \"24652973\"},\n        {\"claim\": \"SOCS proteins induced by TAM signaling suppress cytokine signaling\", \"pmid\": \"16343641\"},\n        {\"claim\": \"Mertk deficiency increased susceptibility to neuroinvasive infection\", \"pmid\": \"26523970\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"PMID:25217958 discusses dengue and FcγR-dependent entry, not direct LDLR usage - overgeneralization\", \"pmid\": \"25217958\"},\n        {\"claim\": \"No direct evidence linking TAM signaling to LDLR/VLDLR expression on brain endothelium\", \"pmid\": null},\n        {\"claim\": \"Brain endothelial cells express minimal LDLR compared to peripheral endothelium\", \"pmid\": null},\n        {\"claim\": \"Doesn't explain peripheral immune response defects - Mertk-/- mice show enhanced replication in spleen/lymph nodes\", \"pmid\": \"26523970\"}\n      ],\n      \"key_citations\": [\"25217958\", \"24652973\", \"16343641\"],\n      \"recommended_experiments\": [\n        \"Measure LDLR/VLDLR/LRP1 mRNA and protein on brain endothelial cells in WT vs Mertk-/-\",\n        \"Test LDLR/VLDLR blocking antibodies in Mertk-/- mice\",\n        \"Use LDLR-independent entry viruses (e.g., HSV-1 via nectin-1)\"\n      ],\n      \"development_timeline\": \"Not recommended - requires fundamental biology first\",\n      \"risk_factors\": [\"LDLR modulation affects cholesterol homeostasis - cardiovascular risk\", \"SOCS-dependent mechanism is generic and unfalsifiable with respect to TAM specificity\"],\n      \"unifying_theme\": \"TAM signaling may suppress expression of viral entry receptors to block CNS invasion, though evidence is highly indirect\"\n    },\n    {\n      \"rank\": 5,\n      \"id\": \"H3\",\n      \"title\": \"Glial Cell Homeostasis Protection Hypothesis\",\n      \"composite_score\": 0.35,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.35,\n        \"evidence_strength\": 0.30,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.30,\n        \"therapeutic_potential\": 0.40,\n        \"druggability\": 0.30,\n        \"safety_profile\": 0.30,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.35,\n        \"reproducibility\": 0.35\n      },\n      \"evidence_for\": [\n        {\"claim\": \"MERTK is highly expressed on microglia and is critical for microglial phagocytic function\", \"pmid\": \"29141986\"},\n        {\"claim\": \"Microglial senescence and SASP driving neuroinflammation documented\", \"pmid\": \"29980634\"},\n        {\"claim\": \"Enhanced inflammatory response in Mertk-deficient mice\", \"pmid\": \"26523970\"},\n        {\"claim\": \"TAM receptor deficiency leads to impaired clearance of cellular debris\", \"pmid\": \"20844263\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"SASP develops over days to weeks - fundamentally incompatible with acute viral infection timeframe (hours-days)\", \"pmid\": null},\n        {\"claim\": \"PMID:29141986 shows MERTK regulates phagocytosis, not senescence - evidence doesn't directly support mechanism\", \"pmid\": \"29141986\"},\n        {\"claim\": \"p16INK4a expression in microglia is controversial - can be upregulated without full senescence\", \"pmid\": null},\n        {\"claim\": \"High IL-6/CXCL10 could be response to higher viral loads, not primary microglial senescence\", \"pmid\": null}\n      ],\n      \"key_citations\": [\"29141986\", \"29980634\", \"26523970\", \"20844263\"],\n      \"recommended_experiments\": [\n        \"p16INK4a reporter assay (Cdkn2a-tdTomato) in microglia at 1, 3, 5 dpi in WT vs Mertk-/-\",\n        \"Senolytic (ABT-263) treatment before infection in Mertk-/- mice\",\n        \"Single-cell RNA-seq of microglia at 24h post-infection\"\n      ],\n      \"development_timeline\": \"Not recommended - timescale incompatibility is fundamental\",\n      \"risk_factors\": [\"Senolytic drugs have significant toxicity (myelosuppression)\", \"Senolytics kill senescent cells, opposite of what's needed\", \"No validated microglial senescence biomarkers\"],\n      \"unifying_theme\": \"MERTK may prevent microglial senescence and SASP to preserve CNS homeostasis, but SASP cannot explain acute phenotype\"\n    },\n    {\n      \"rank\": 6,\n      \"id\": \"H6\",\n      \"title\": \"Astrocyte-Neuron Metabolic Coupling Protection\",\n      \"composite_score\": 0.30,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.30,\n        \"evidence_strength\": 0.30,\n        \"novelty\": 0.70,\n        \"feasibility\": 0.25,\n        \"therapeutic_potential\": 0.30,\n        \"druggability\": 0.15,\n        \"safety_profile\": 0.45,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.25,\n        \"reproducibility\": 0.35\n      },\n      \"evidence_for\": [\n        {\"claim\": \"Astrocyte metabolic support critical for neuronal survival during stress\", \"pmid\": \"27908931\"},\n        {\"claim\": \"Astrocyte dysfunction in viral CNS infection documented\", \"pmid\": \"29704498\"},\n        {\"claim\": \"HMGB1 release from dying cells triggers neuroinflammation and BBB disruption\", \"pmid\": \"24316865\"},\n        {\"claim\": \"MERTK expressed on astrocytes and regulates cellular metabolism\", \"pmid\": \"29141986\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"PMID:29141986 primarily addresses microglial MERTK - direct evidence for astrocyte MERTK is weak\", \"pmid\": \"29141986\"},\n        {\"claim\": \"HMGB1 release is consequence of cell death, not early driver of BBB disruption\", \"pmid\": null},\n        {\"claim\": \"Glut1/LDHA regulation by MERTK not demonstrated - no mechanistic link\", \"pmid\": null},\n        {\"claim\": \"Metabolic reprogramming takes hours to days - viral neuroinvasion can occur within 24-48 hours\", \"pmid\": null},\n        {\"claim\": \"Astrocytes are relatively resistant to many neurotropic viruses - primary targets are neurons\", \"pmid\": null}\n      ],\n      \"key_citations\": [\"27908931\", \"29704498\", \"24316865\", \"29141986\"],\n      \"recommended_experiments\": [\n        \"Astrocyte-specific Mertk deletion (Aldh1l1-CreERT2)\",\n        \"Measure astrocyte metabolic gene expression (Glut1, Ldha, GLAST) at baseline and during infection\",\n        \"Lactate supplementation rescue experiments\"\n      ],\n      \"development_timeline\": \"Not recommended - requires too many unsupported assumptions\",\n      \"risk_factors\": [\"Systemic metabolic manipulation has pleiotropic effects\", \"No astrocyte-specific MERTK modulators exist\", \"Metabolic endpoints difficult to measure in vivo\"],\n      \"unifying_theme\": \"MERTK signaling may maintain astrocyte metabolic support for neurons, but mechanism is highly speculative and timing incompatible\"\n    },\n    {\n      \"rank\": 7,\n      \"id\": \"H7\",\n      \"title\": \"Epigenetic 'Trained Innate Immunity' Induction Hypothesis\",\n      \"composite_score\": 0.29,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.20,\n        \"evidence_strength\": 0.25,\n        \"novelty\": 0.60,\n        \"feasibility\": 0.20,\n        \"therapeutic_potential\": 0.25,\n        \"druggability\": 0.10,\n        \"safety_profile\": 0.20,\n        \"competitive_landscape\": 0.70,\n        \"data_availability\": 0.25,\n        \"reproducibility\": 0.15\n      },\n      \"evidence_for\": [\n        {\"claim\": \"Trained immunity via epigenetic modifications documented\", \"pmid\": \"27500629\"},\n        {\"claim\": \"TAM receptor signaling regulates gene expression beyond immediate signaling\", \"pmid\": \"23995677\"},\n        {\"claim\": \"Mertk deficiency led to dysregulated immune response\", \"pmid\": \"26523970\"},\n        {\"claim\": \"Epigenetic regulation of neuroinflammation well-established\", \"pmid\": \"28392442\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"FUNDAMENTAL TIMESCALE INCOMPATIBILITY: Trained immunity requires days-weeks; acute pathology occurs within hours-days\", \"pmid\": null},\n        {\"claim\": \"PMID:27500629 addresses β-glucan training, not TAM signaling - category error\", \"pmid\": \"27500629\"},\n        {\"claim\": \"PMID:23995677 addresses signaling cascades, not epigenetic programming - direct link assumed not demonstrated\", \"pmid\": \"23995677\"},\n        {\"claim\": \"Germline vs acute treatment conflation: uses constitutive KO to generate acute treatment predictions\", \"pmid\": null},\n        {\"claim\": \"Epigenetic changes require cell division; microglia/astrocytes are largely post-mitotic in adults\", \"pmid\": null}\n      ],\n      \"key_citations\": [\"27500629\", \"23995677\", \"26523970\", \"28392442\"],\n      \"recommended_experiments\": [\n        \"Acute MERTK blockade in adult WT mice before infection (vs germline KO)\",\n        \"ATAC-seq/ChIP-seq on microglia from WT vs Mertk-/- at baseline\",\n        \"Pre-treatment (not germline) with TAM agonists vs co-treatment comparison\"\n      ],\n      \"development_timeline\": \"Should be abandoned for acute viral infection\",\n      \"risk_factors\": [\"Epigenetic drugs in CNS are notoriously challenging\", \"No TAM-specific epigenetic drugs exist\", \"Systemic TAM agonism for trained immunity would cause immunosuppression in acutely infected patients\"],\n      \"unifying_theme\": \"TAM agonism may induce protective epigenetic programming, but mechanism is fundamentally incompatible with acute viral infection pathology\"\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source\": \"MERTK\",\n      \"edge_type\": \"receptor\",\n      \"target\": \"PROS1/GAS6\",\n      \"relationship\": \"binds\",\n      \"context\": \"Ligand-mediated activation initiates downstream signaling\"\n    },\n    {\n      \"source\": \"MERTK\",\n      \"edge_type\": \"regulates\",\n      \"target\": \"SOCS1/SOCS3\",\n      \"relationship\": \"induces\",\n      \"context\": \"TAM receptor signaling suppresses TLR signaling via SOCS induction\",\n      \"pmid\": \"16343641\"\n    },\n    {\n      \"source\": \"MERTK\",\n      \"edge_type\": \"mediates\",\n      \"target\": \"efferocytosis\",\n      \"relationship\": \"enables\",\n      \"context\": \"Clearance of phosphatidylserine-exposing apoptotic cells\",\n      \"pmid\": \"16148958\"\n    },\n    {\n      \"source\": \"MERTK\",\n      \"edge_type\": \"expressed_on\",\n      \"target\": \"microglia\",\n      \"relationship\": \"maintains\",\n      \"context\": \"Critical for microglial phagocytic function and homeostasis\",\n      \"pmid\": \"29141986\"\n    },\n    {\n      \"source\": \"MERTK\",\n      \"edge_type\": \"modulates\",\n      \"target\": \"IFN response\",\n      \"relationship\": \"regulates\",\n      \"context\": \"May gate protective vs damaging type I IFN signaling\",\n      \"pmid\": \"27279225\"\n    },\n    {\n      \"source\": \"PROS1\",\n      \"edge_type\": \"binds\",\n      \"target\": \"phosphatidylserine\",\n      \"relationship\": \"bridges\",\n      \"context\": \"Binds both cellular and viral phosphatidylserine\",\n      \"pmid\": \"20194607\"\n    },\n    {\n      \"source\": \"TNF-α\",\n      \"edge_type\": \"disrupts\",\n      \"target\": \"tight_junctions\",\n      \"relationship\": \"degrades\",\n      \"context\": \"Pro-inflammatory cytokine compromises BBB integrity\",\n      \"pmid\": \"10760258\"\n    },\n    {\n      \"source\": \"STAT1\",\n      \"edge_type\": \"regulates\",\n      \"target\": \"MMP9/MMP2\",\n      \"relationship\": \"induces\",\n      \"context\": \"IFN signaling drives matrix metalloproteinase expression\",\n      \"pmid\": \"29491009\"\n    },\n    {\n      \"source\": \"MMP9\",\n      \"edge_type\": \"degrades\",\n      \"target\": \"tight_junctions\",\n      \"relationship\": \"compromises\",\n      \"context\": \"BBB disruption via tight junction protein degradation\",\n      \"pmid\": \"25666004\"\n    },\n    {\n      \"source\": \"IFNAR1/2\",\n      \"edge_type\": \"mediates\",\n      \"target\": \"type_I_IFN\",\n      \"relationship\": \"signals\",\n      \"context\": \"Generally protective in neurotropic viral infections\",\n      \"pmid\": \"16439465\"\n    },\n    {\n      \"source\": \"LDLR/VLDLR\",\n      \"edge_type\": \"mediates\",\n      \"target\": \"viral_entry\",\n      \"relationship\": \"entry_receptor\",\n      \"context\": \"May serve as entry portals for some neurotropic viruses\",\n      \"pmid\": \"25217958\"\n    },\n    {\n      \"source\": \"AXL\",\n      \"edge_type\": \"binds\",\n      \"target\": \"Zika_virus\",\n      \"relationship\": \"entry_receptor\",\n      \"context\": \"Some viruses directly use TAM receptors for cell entry\",\n      \"pmid\": \"27152518\"\n    },\n    {\n      \"source\": \"HMGB1\",\n      \"edge_type\": \"released_from\",\n      \"target\": \"dying_cells\",\n      \"relationship\": \"triggers\",\n      \"context\": \"DAMP release drives neuroinflammation and BBB disruption\",\n      \"pmid\": \"24316865\"\n    },\n    {\n      \"source\": \"p16INK4a\",\n      \"edge_type\": \"marker_of\",\n      \"target\": \"cellular_senescence\",\n      \"relationship\": \"associated\",\n      \"context\": \"SASP development in glial cells during chronic inflammation\",\n      \"pmid\": \"29980634\"\n    },\n    {\n      \"source\": \"H3K4me3\",\n      \"edge_type\": \"epigenetic_mark\",\n      \"target\": \"antiviral_genes\",\n      \"relationship\": \"activates\",\n      \"context\": \"Trained immunity marker at ISG promoters\",\n      \"pmid\": \"27500629\"\n    },\n    {\n      \"source\": \"TMEM119\",\n      \"edge_type\": \"marker\",\n      \"target\": \"microglia\",\n      \"relationship\": \"identifies\",\n      \"context\": \"Microglial cell-specific marker\"\n    }\n  ],\n  \"pathway_interactions\": [\n    {\n      \"pathway_name\": \"TAM-SOCS-TLR axis\",\n      \"components\": [\"MERTK/AXL → SOCS1/SOCS3 → TLR signaling suppression\"],\n      \"disease_relevance\": \"Controls magnitude of innate immune response to viral infection\",\n      \"evidence_pmid\": \"16343641\"\n    },\n    {\n      \"pathway_name\": \"Efferocytosis-viral clearance axis\",\n      \"components\": [\"MERTK + PROS1/GAS6 → phosphatidylserine recognition → apoptotic cell clearance\"],\n      \"disease_relevance\": \"Prevents viral spread from infected apoptotic debris; deficiency leads to enhanced viral replication\",\n      \"evidence_pmid\": \"26523970,16148958\"\n    },\n    {\n      \"pathway_name\": \"Inflammatory-BBB disruption axis\",\n      \"components\": [\"TNF-α/IL-1β → tight junction degradation → BBB compromise → neuroinvasion\"],\n      \"disease_relevance\": \"Excessive inflammation compromises BBB, enabling viral CNS entry\",\n      \"evidence_pmid\": \"10760258,26523970\"\n    },\n    {\n      \"pathway_name\": \"IFN-STAT-MMP axis\",\n      \"components\": [\"Type I IFN → IFNAR → JAK-STAT → STAT1/3 → MMP9/2 → tight junction degradation\"],\n      \"disease_relevance\": \"Sustained IFN signaling may paradoxically damage BBB\",\n      \"evidence_pmid\": \"29491009,25666004\"\n    },\n    {\n      \"pathway_name\": \"Glial senescence-inflammation axis\",\n      \"components\": [\"MERTK deficiency → microglial senescence → SASP (IL-6, CXCL10) → BBB disruption\"],\n      \"disease_relevance\": \"Senescent microglia drive chronic neuroinflammation\",\n      \"evidence_pmid\": \"29980634,29141986\"\n    }\n  ],\n  \"synthesis_summary\": {\n    \"primary_conclusion\": \"The paradox of TAM receptor 'immunosuppression' protecting against neuroinvasive viruses resolves through the re-interpretation of TAM signaling as protective immune regulation that prevents collateral CNS damage while enabling antiviral clearance. The most parsimonious explanation is that TAM receptors contribute to antiviral immunity in specific cell types, and their deficiency leads to uncontrolled viral replication both peripherally and in the CNS, with secondary effects on neuroinflammation.\",\n    \"top_3_hypotheses_for_investigation\": [\n      {\n        \"rank\": 1,\n        \"id\": \"H2\",\n        \"title\": \"Phagocytic 'Viral Sink' Clearance Mechanism\",\n        \"",
  "tokens_used": "5757",
  "persona_id": "persona-synthesizer"
}